Literature DB >> 21615093

Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.

Wook Lee1, Sylvia R Luckner, Caroline Kisker, Peter J Tonge, Bernd Engels.   

Abstract

KasA (β-ketoacyl ACP synthase I) is involved in the biosynthetic pathway of mycolic acids, an essential component of the cell wall in Mycobacterium tuberculosis. It was shown that KasA is essential for the survival of the pathogen and thus could serve as a new drug target for the treatment of tuberculosis. The active site of KasA was previously characterized by X-ray crystallography. However, questions regarding the protonation state of specific amino acids, the orientation of the histidine groups within the active site, and additional conformers being accessible at ambient temperatures remain open and have to be addressed prior to the design of new inhibitors. We investigate the active site of KasA in this work by means of structural motifs and relative energies. Molecular dynamics (MD) simulations, free energy perturbation computations, and calculations employing the hybrid quantum mechanics/molecular mechanics (QM/MM) method made it possible to determine the protonation status and reveal important details about the catalytic mechanism of KasA. Additionally, we can rationalize the molecular basis for the acyl-transfer activity in the H311A mutant. Our data strongly suggest that inhibitors should be able to inhibit different protonation states because the enzyme can switch easily between a zwitterionic and neutral state.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615093      PMCID: PMC4397578          DOI: 10.1021/bi200006t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  The crystal structure of beta-ketoacyl-acyl carrier protein synthase II from Synechocystis sp. at 1.54 A resolution and its relationship to other condensing enzymes.

Authors:  M Moche; K Dehesh; P Edwards; Y Lindqvist
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

Review 2.  The structural biology of type II fatty acid biosynthesis.

Authors:  Stephen W White; Jie Zheng; Yong-Mei Zhang
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

3.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

4.  The implementation of a fast and accurate QM/MM potential method in Amber.

Authors:  Ross C Walker; Michael F Crowley; David A Case
Journal:  J Comput Chem       Date:  2008-05       Impact factor: 3.376

5.  DL_POLY_2.0: a general-purpose parallel molecular dynamics simulation package.

Authors:  W Smith; T R Forester
Journal:  J Mol Graph       Date:  1996-06

6.  beta-Ketoacyl-[acyl carrier protein] synthase I of Escherichia coli: aspects of the condensation mechanism revealed by analyses of mutations in the active site pocket.

Authors:  K A McGuire; M Siggaard-Andersen; M G Bangera; J G Olsen; P von Wettstein-Knowles
Journal:  Biochemistry       Date:  2001-08-21       Impact factor: 3.162

7.  Fatty acid synthesis. Role of active site histidines and lysine in Cys-His-His-type beta-ketoacyl-acyl carrier protein synthases.

Authors:  Penny von Wettstein-Knowles; Johan G Olsen; Kirsten A McGuire; Anette Henriksen
Journal:  FEBS J       Date:  2006-02       Impact factor: 5.542

8.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Authors:  R A Slayden; R E Lee; J W Armour; A M Cooper; I M Orme; P J Brennan; G S Besra
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Molecular modeling and simulation of Mycobacterium tuberculosis cell wall permeability.

Authors:  Xuan Hong; A J Hopfinger
Journal:  Biomacromolecules       Date:  2004 May-Jun       Impact factor: 6.988

Review 10.  Extensively drug-resistant tuberculosis: current challenges and threats.

Authors:  Amita Jain; Rajesh Mondal
Journal:  FEMS Immunol Med Microbiol       Date:  2008-05-08
View more
  5 in total

1.  Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.

Authors:  Benjamin Schaefer; Caroline Kisker; Christoph A Sotriffer
Journal:  J Comput Aided Mol Des       Date:  2011-11-11       Impact factor: 3.686

2.  Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.

Authors:  Johannes Schiebel; Kanishk Kapilashrami; Agnes Fekete; Gopal R Bommineni; Christin M Schaefer; Martin J Mueller; Peter J Tonge; Caroline Kisker
Journal:  J Biol Chem       Date:  2013-10-09       Impact factor: 5.157

3.  Investigation of Structural Dynamics of Enzymes and Protonation States of Substrates Using Computational Tools.

Authors:  Chia-En A Chang; Yu-Ming M Huang; Leonard J Mueller; Wanli You
Journal:  Catalysts       Date:  2016-05-31       Impact factor: 4.146

4.  Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.

Authors:  Pradeep Kumar; Glenn C Capodagli; Divya Awasthi; Matthew B Neiditch; Joel S Freundlich; David Alland; Riju Shrestha; Karishma Maharaja; Paridhi Sukheja; Shao-Gang Li; Daigo Inoyama; Matthew Zimmerman; Hsin Pin Ho Liang; Jansy Sarathy; Marizel Mina; George Rasic; Riccardo Russo; Alexander L Perryman; Todd Richmann; Aditi Gupta; Eric Singleton; Sheetal Verma; Seema Husain; Patricia Soteropoulos; Zhe Wang; Roxanne Morris; Gene Porter; Gautam Agnihotri; Padmini Salgame; Sean Ekins; Kyu Y Rhee; Nancy Connell; Véronique Dartois
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

Review 5.  Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design.

Authors:  Reshma S Rudraraju; Samer S Daher; Ricardo Gallardo-Macias; Xin Wang; Matthew B Neiditch; Joel S Freundlich
Journal:  Front Cell Infect Microbiol       Date:  2022-09-15       Impact factor: 6.073

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.